Fisher & Paykel Healthcare Corporation Limited received a Buy rating and price target from Citi analyst Laura Sutcliffe today.
According to TipRanks, Sutcliffe is a 3-star analyst with an average return of 1.3% and a 50.29% success rate. Sutcliffe covers the Healthcare sector, focusing on stocks such as CSL, Telix Pharmaceuticals, and Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh.
Currently, the analyst consensus on Fisher & Paykel Healthcare Corporation Limited is a Moderate Buy with an average price target of $27.43.
Based on Fisher & Paykel Healthcare Corporation Limited’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of N$1.24 billion and a net profit of N$255.5 million. In comparison, last year the company earned a revenue of N$989.9 million and had a net profit of N$207.27 million
Based on the recent corporate insider activity of 21 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of FSPKF in relation to earlier this year.
